Airway smooth muscle enlargement is associated with protease-activated receptor 2/ligand overexpression in patients with difficult-to-control severe asthma

详细信息    查看全文

• 作者：Michel Aubier ; MD^a ; ^b ; ^c ; ^e ; ^f ; ^h ; ⁱ ; Gabriel Thabut ; MD ; PhD^a ; ^b ; ^d ; ^f ; ^h ; ⁱ ; Fatima Hamidi ; MSc^a ; ^b ; ^h ; ⁱ ; Noë ; lline Guillou ; MSc^a ; ^b ; ^h ; ⁱ ; Julien Brard ; MSc^a ; ^b ; ^h ; ⁱ ; Marie-Christine Dombret ; MD^a ; ^b ; ^c ; ^e ; ^f ; ^h ; ⁱ ; Keren Borensztajn ; PhD^a ; ^b ; ^h ; ⁱ ; Brahim Aitilalne ; MSc^a ; ^b ; ^g ; ^h ; ⁱ ; Isabelle Poirier ; BNBP^a ; ^b ; ^h ; ⁱ ; Pascale Roland-Nicaise ; PharmD ; PhD^b ; ^c ; ^f ; Camille Taillé ; MD ; PhD^a ; ^b ; ^c ; ^e ; ^f ; ^h ; ⁱ ; Marina Pretolani ; PharmD ; PhD^a ; ^b ; ^h ; ⁱ ; ^{marina.pretolani@inserm.fr" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Airway remodeling ; asthma control ; mast cells ; tryptase ; protease-activated receptor 2 ; kallikreins
• 刊名：Journal of Allergy and Clinical Immunology
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：138
• 期：3
• 页码：729-739.e11
• 全文大小：2613 K

文摘

Asthma is a complex disease with heterogeneous features of airway inflammation and remodeling. The increase in airway smooth muscle (ASM) mass is an essential component of airway remodeling in patients with severe asthma, yet the pathobiological mechanisms and clinical outcomes associated with ASM enlargement remain elusive.

Objective

15">We sought to compare ASM area in control subjects and patients with mild-to-moderate or severe asthma and to identify specific clinical and pathobiological characteristics associated with ASM enlargement.

Methods

Bronchial biopsy specimens from 12 control subjects, 24 patients with mild-to-moderate asthma, and 105 patients with severe asthma were analyzed for ASM area, basement membrane thickness, vessels, eosinophils, neutrophils, T lymphocytes, mast cells, and protease-activated receptor 2 (PAR-2). In parallel, the levels of several ASM mitogenic factors, including the PAR-2 ligands, mast cell tryptase, trypsin, tissue factor, and kallikrein (KLK) 5 and KLK14, were assessed in bronchoalveolar lavage fluid. Data were correlated with asthma severity and control both at inclusion and after 12 to 18 months of optimal management and therapy.

Results

Analyses across ASM quartiles in patients with severe asthma demonstrated that patients with the highest ASM quartile (median value of ASM area, 26.3%) were younger (42.5 vs ≥50 years old in the other groups, P ≤ .04) and had lower asthma control after 1 year of optimal management (P ≤ .006). ASM enlargement occurred independently of features of airway inflammation and remodeling, whereas it was associated with PAR-2 overexpression and higher alveolar tryptase (P ≤ .02) and KLK14 (P ≤ .03) levels.

Conclusion

Increase in ASM mass, possibly involving aberrant expression and activation of PAR-2–mediated pathways, characterizes younger patients with severe asthma with poor asthma control.